survival
Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future.
A study showed "unexpected" results related to race and MDS survival...
The efficacy of enasidenib in patients with AML depends on the mutation type.
Advertisement
The addition of brentuximab vedotin improved survival in Hodgkin lymphoma.
A new model that makes use of a promising imaging biomarker can predict diffuse large B-cell lymphoma relapse and survival ...
The expression patterns and clinical significances of CD300s in cancers are still not well understood.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.